Treatment Modalaties

Kinase Inhibitors

Pazopanib and sunitinib is a kinase inhibitor that blocks tumour progression via VEGFR and PDGFR receptors inhibition. This ultimately led to disruption of the PI3K/Akt signalling cascade. Most commonly used chemotherapeutic agent for treating SFT/HPC patients. Sunitinib is an ideal candidate to treat Malignant SFT. In SFT, kinase inhibitors, and action mechanisms, have not been sufficiently studied yet. In the dedifferentiated SFT Xenograft model, pazopanib induced a marginal antitumour activity, while regorafenib appeared to have the most active and promising effect on the tumour cells.

Anthracycline-based Chemotherapy

Anthracycline blocks DNA and RNA synthesis in cells. Studies have shown that anthracycline-based Chemotherapy is the most suitable form of therapy to treat patients with advanced SFT.

Chromeceptin

Chromeceptin is an Insulin-like growth factor 2 (IGF2) via multifunctional protein 2 (MFP-2) and thereby activating STAT6 and also upregulates IGFBP-1. This IGFBP-1 confiscates IGF2 protein from binding with its receptor. Results suggest that upon chromeceptin administration on IGF2 upregulated in NIH-3T3 cells, there was suppressed proliferation and migration on them.